BiotechTube

Rocuronium Bromide + Rocuronium Bromide

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Neuromuscular Blockade

Conditions

Neuromuscular Blockade, Innate Inflammatory Response, Quality of Life, Postoperative Complications

Trial Timeline

Nov 18, 2022 → Aug 29, 2024

NCT ID
NCT05562999

About Rocuronium Bromide + Rocuronium Bromide

Rocuronium Bromide + Rocuronium Bromide is a approved stage product being developed by Merck for Neuromuscular Blockade. The current trial status is completed. This product is registered under clinical trial identifier NCT05562999. Target conditions include Neuromuscular Blockade, Innate Inflammatory Response, Quality of Life.

What happened to similar drugs?

14 of 20 similar drugs in Neuromuscular Blockade were approved

Approved (14) Terminated (2) Active (6)
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
✅Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
✅neostigmine/glycopyrrolate + sugammadexMerckApproved
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
✅Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05562999ApprovedCompleted

Competing Products

20 competing products in Neuromuscular Blockade

See all competitors
ProductCompanyStageHype Score
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
35
Placebo + Sugammadex + Esmeron®MerckPhase 2
35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
43
Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
39
Rocuronium + Succinylcholine + Cisatracurium + Mivacurium + Sugammadex + NeostigmineMerckPre-clinical
26
Sugammadex + RocuroniumMerckApproved
43
sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
43
neostigmine/glycopyrrolate + sugammadexMerckApproved
43
sugammadexMerckPhase 3
40
2 mg/kg sugammadex + 0.07 mg/kg neostigmineMerckPhase 3
47
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
43
Rocuronium + Sugammadex + Cisatracurium + Neostigmine/Atropine + SuccinylcholineMerckApproved
35
Sugammadex + NeostigmineMerckApproved
43
Sugammadex 2 mg/kg ABW + Sugammadex 2 mg/kg IBW + Sugammadex 4 mg/kg ABW + Sugammadex 4 mg/kg IBW + Neostigmine + Glycopyrrolate + Rocuronium or VecuroniumMerckApproved
43
sugammadex + Neostigmine + GlycopyrrolateMerckApproved
43
Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline + Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;MerckPhase 2
35
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved
43
Rocuronium (moderate NMB) + Rocuronium (deep NMB)MerckPre-clinical
22